A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Investigate the Efficacy, Safety, and PK/ PD of Finerenone, in Addition to Standard-of-care, in Pediatric Patients, 6 Months to < 18 Years of Age With Heart Failure (HF) and Left Ventricular Systolic Dysfunction (LVSD)
Latest Information Update: 05 Nov 2025
At a glance
- Drugs Finerenone (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms FIORE
- Sponsors Bayer
Most Recent Events
- 14 Oct 2025 Planned initiation date changed from 30 Sep 2025 to 30 Oct 2025.
- 29 Sep 2025 New trial record